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CASE PRESENTATION
Two female siblings (patient 1: 12 6/12; Patient 2: 7 3/12
years old) of consanguineous parents, presented with
hematuria and proteinuria at five years (Patient 1) and six
months (Patient 2) of age, respectively. Clinical examination,
renal ultrasonography and laboratory analyses resulted
normal, and both patients were normotensive.
Detailed complement analyses, however,
demonstrated activation of the alternative complement
pathway reflected by decreased C3 and Factor B (FB), and
increased C3d, while C4 was normal. The Factor H (CFH)
gene (CFH) had a deletion of a single amino acid (Lysine)
in position 224 (DK224) within its complement regulatory
region in short consensus repeat 4 (SCR 4). In addition,
both patients and also the healthy mother were C3
nephritic factor (C3NeF) positive. Renal biopsy in Patient 1
at five years of age prior to therapy (biopsy 1.1) was
initially interpreted as membranoproliferative
glomerulonephritis type II/dense deposit disease (MPGN
II/DDD). Chronic treatment with fresh frozen plasma (FFP)
was initiated in both patients (10–15 mL FFP/kg body
weight/14 d). A follow-up biopsy of Patient 1 after two
years of periodical FFP-infusion (biopsy 1.2) showed no
disease progression as compared to the pre-treatment
biopsy. This is to our knowledge the first report of
successful long-term treatment with periodical FFP-
infusion of such patients. Renal biopsy of Patient 2
(Biopsy 2) in whom no pre-treatment biopsy had been
performed confirmed both the same diagnosis and the
level of disease severity as observed in Patient 1.
Furthermore, in light of the recent description of
patients with a phenotypical spectrum of glomerular
pathology termed glomerulonephritis C3 (we suggest the
term ‘C3 deposition glomerulopathy (C3DG)’ which more
precisely describes the pathological changes in the
glomerulus than ‘glomerulonephritis C3 (GN C3)’ does.)
which is also caused by dysregulation of the alternative
complement pathway, including complement deposition
within the glomerular basement membrane (GBM), the
subendothelial and mesangial space, the diagnosis of the two
patients could be specified as fitting into this disease group.
In summary, chronic treatment with periodical
FFP-infusion was successful in preventing disease
progression in two patients with C3 deposition
glomerulopathy (C3DG) caused by alternative
complement pathway dysregulation because of
dysfunctional CFH and C3NeF.
PATHOLOGY
Renal biopsies were performed in patient 1 at 5 years of age
before therapy (biopsy 1.1) and in both patients, patients 1
and 2, following 2 years of therapy (patient 1: biopsy 1.2;
patient 2: biopsy 2). Results of these biopsies are summarized
in the following.
Light microscopy
The renal biopsies had 15 (biopsy 1.1), 25 (biopsy 1.2), and
27 (biopsy 2) glomeruli, respectively. The glomeruli showed
mild mesangial widening, without hypercellularity, and very
rare and small mesangial protein deposits. In the peripheral
loops, no significant abnormalities were found. Tubulointer-
stitial and vascular lesions were absent (Figure 1).
Immunohistochemistry
All glomeruli in the follow-up biopsy of patient 1 (biopsy
1.2) and the biopsy of patient 2 (biopsy 2) showed prominent
mesangial deposits of C3 and even more extensive deposits of
C5b-9. Peripheral deposits were far less prominent. Minor
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deposits of both complement components were present in
the basement membrane of Bowman’s capsule. No other
deposits were found in glomeruli and/or vessels. The first
biopsy of patient 1 (biopsy 1.1) was positive for C3c and C3d
in the mesangium and the peripheral loops only (Figure 1).
Electron microscopy
Electron microscopy investigations were performed immedi-
ately on the follow-up biopsy of patient 1 (biopsy 1.2) and
the biopsy of patient 2 (biopsy 2). In both cases, the
glomerular structures were well preserved. By low power
magnification, slight mesangial enlargement was seen in a few
areas, but no deposits were present in the mesangium or in
the peripheral loops. Higher magnifications showed a few
small nodular or short linear deposits in the mesangial matrix
and along the mesangial basement membrane, respectively. In
the peripheral loops, some basement membranes exhibited
small roundish deposits, mostly within the basement
membrane and rarely in a subendothelial position. Short
linear deposits were present only in one area. Typical
hyperosmiophilia of the deposits, as seen in membranopro-
liferative glomerulonephritis type II/dense deposit disease
(MPGN II/DDD), was not present. Structured deposits were
not found. Complete podocyte foot process fusion and very
mild activation of endothelial cells accompanied the lesions
described. No abnormalities were noted in the tubulointer-
stitial space or in the vessels. The primarily snap-frozen
biopsy of patient 1 (biopsy 1.1) was first studied by
immunofluorescence, then embedded in paraffin and finally
in epon, and investigated by electron microscopy. Despite
massive artefacts, the character and distribution of deposits
was the same as described above (Figure 2).
Taken together, these findings indicate the pathomorpho-
logical diagnosis of a complement deposition glomerulo-
pathy (glomerulonephritis) with prominent C3 and even
more prominent C5b-9 deposits in the mesangium and less
in the peripheral capillary loops, minor glomerular abnorm-
alities by light microscopy, as well as few non-hyperosmio-
philia deposits in the mesangium and the peripheral capillary
loops. Of note, this morphology is similar, if not identical, to
the cases described by Servais et al.1 as glomerulonephritis
with isolated C3 deposits.
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Figure 1 | Representative images of biopsies 1.1 and 1.2 of patient 1 (a–c), and of biopsy 2 of patient 2 (d, e). (a) Biopsy 1.1: Minimal
mesangial matrix increase, no hypercellularity (PAS stain;  400). (b) Biopsy 1.2: Minimal mesangial matrix increase, no hypercellularity
(PAS stain;  400). (c) Biopsy 1.2: Immunohistochemistry in paraffin sections for complement C3 showing prominent mesangial and
minimal peripheral staining (complement C3 from Dako, Glostrup, Denmark ;  400). (d, e) Minimal mesangial matrix increase without
hypercellularity or mesangial deposits, questionable minimal thickening of the peripheral basement membranes (e) (d: PAS stain,  400;
e: silver stain,  400). (f) Immunohistochemistry in paraffin sections for complement C5b-9 showing prominent mesangial and peripheral
staining (complement C5b-9 from Dako,  400).
Figure 2 | Typical electron microscopic picture characteristic
for both patients. Numerous osmiophilic deposits in the
mesangium and in the loop periphery, either intramembranous or
subendothelial (arrows). No linear hypereosinophilic deposits.
(Primary fixation in buffered formalin (4%), postfixation in
glutaraldehyde (3%),  4400).
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DIFFERENTIAL DIAGNOSIS
The following stepwise diagnostic approach was applied to
the two patients when they first presented with hematuria
and proteinuria (Table 1; Figure 3).
Alternative complement pathway activation was examined
measuring C3, C3d, C4, CH50, APH50, and in addition, C3
nephritic factor (C3NeF), C3NeF was measured. In both
patients, biochemical work-up revealed activation of the
alternative complement pathway with decreased C3 (patient
1: 0.19 g/l; patient 2: 0.16 g/l; normal 0.75–1.43 g/l) and
increased C3d (patient 1: 156 mU/l; patient 2: 144 mU/l;
normal o40 mU/l). APH50 (alternative complement path-
way activity) was reduced in both patients (patient 1: 35%;
patient 2: 14%; normal 60–140%). In addition, both patients
and the healthy mother were positive for C3NeF. As factor H
(CFH), plasma concentration was only slightly reduced
(patient 1: 130 mg/ml; patient 2: 154 mg/ml; normal
284–528 mg/ml), genetic analyses were performed that
identified a compound heterozygous CFH mutation resulting
in impaired complement regulatory activity of CFH in both
patients.2 Taken together, these results indicated a glomer-
ulonephritis with activation of the alternative complement
pathway.
In keeping with a complement-based pathogenetic con-
cept, the light microscopic picture as well as the immuno-
histochemical findings with C3 and C5b-9 deposits in the
glomeruli were interpreted as MPGN II/DDD (Figure 1). At
the ultrastructural level (electron microscopy), however, the
findings were not compatible with MPGN II/DDD. The
diagnosis MPGN II/DDD requires linear dense (that is,
hyperosmiophilia) deposits within the peripheral basement
membrane and in the mesangium (Figure 4). As, however,
such deposits were not present in the biopsies of the two
patients but numerous osmiophilic deposits in the mesan-
gium and in the loop periphery, either intramembranous or
subendothelial, were found (Figure 2), this represents a novel
subgroup of glomerulonephritis that we defined as C3
deposition glomerulopathy (C3DG).
Diagnosis
C3 deposition glomerulopathy.
DISCUSSION
During recent years, a crucial role of the alternative
complement pathway for the pathogenesis of certain
glomerulopathies, for example, MPGN II/DDD and atypical
hemolytic uremic syndrome, has been established.3–6 Disease-
causing are defects in proteins composing or regulating the
alternative complement pathway C3 convertase C3bBb,
which mediates activation of the central complement factor
C3. Numerous soluble (CFH), CFH-related proteins 1 and 3
Table 1 | Spectrum of complement-based renal diseases
Diagnosis Clinical features Complement system Histopathological features
aHUS Acute onset with:
Hemolysis
Thrombocytopenia
Impaired renal function
Neurological symptoms (rare)
Loss of surface complement control:
Mutations resulting in loss (gain*)-of-
function of CFH, FI, FB*, MCP
CFHR1/3 deficiency with/without CFH
autoantibodies
Segmental thickening of GBM with double contours
Congestion of capillaries
Increase in extracellular matrix
C3DG
MPGN II/DDD
Chronic disease with:
Proteinuria
Hematuria
Hypertension
Absence of hematological
symptoms
Loss of systemic complement control:
CFH deficiency
CFH mutations
CFH polymorphisms
C3Nef
Mesangial and subendothelial C3 and C5b-9
deposition with/without mesangial proliferation
Absence of dense deposits within the basement
membranes
Linear hyperosmiophilia (electron dense) deposits
within the basement membranes and nodular
deposits in the mesangium
aHUS, atypical hemolytic uremic syndrome; C3DG, C3 deposition glomerulopathy; C3NeF, C3 nephritic factor; CFH, factor H; CFHR1/3, Factor H-related proteins 1 and 3; FB,
factor B; FI, factor I; GBM, glomerular basement membrane; MCP, membrane cofactor protein (CD 46); MPGN II/DDD, membranoproliferative glomerulonephritis type II/dense
deposit disease
Atypical HUS clinically clearly differs from MPGN II/DDD and C3DG with a rather chronic presentation with hematuria and proteinuria but in most cases without primary renal
failure of the latter.
MPGN II/DDD and C3DG can only be distinguished by histopathological analysis: whereas dense deposits within the lamina densa of the glomerular and tubular basement
membranes are characteristic for MPGN II/DDD, C3DG is defined by absence of these intramembranous dense deposits and presence of mesangial C3- and C5b-9 deposits.
Analysis of systemic complement activation
including C3, C3d, C4, C3NeF, CH50, APH50
Complement system not activated
Consider different
causes of disease
Complement system activated
CFH plasma level
Normal Abnormal
CFH function
Normal
Analyze other complement factors
e.g. CFHR1/3, FI, FB, MCP/CD46
Impaired
CFH autoantibodies
Identify mutations and/or
polymorphisms
CFH sequence
Diagnosis of complement deposition glomerulopathy 
Clinical symptoms and renal biopsy
Figure 3 | Diagnostic work-up of glomerulopathy with
complement deposition.
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(CFHR1/CFHR3); factor I (FI); factor B), and membrane-
inserted proteins (membrane cofactor protein/CD46); decay-
accelerating factor/CD55)) modulate C3bBb activity on host
cells. However, certain tissue surfaces such as the glomerular
basement membrane (GBM) lack membrane-anchored
regulators and, in consequence, exclusively depend on
attached soluble regulators such as CFH.7,8 Mutations of
these regulators or inhibiting autoantibodies impair C3bBb
control, thus allowing for unrestricted progression of the
complement cascade on surfaces, eventually resulting in
disease.4,5 In MPGN II/DDD patients, a positive C3NeF
(C3NeF is an autoantibody that binds to the alternative
complement pathway C3 convertase C3bBb thus decelerating
its decay.),9,10 homozygous, or compound heterozygous CFH
mutations resulting in (absolute or functional) CFH
deficiency,6 CFH autoantibodies,11,12 as well as CFH and
CFHR5 polymorphisms were observed.13
While mesangial deposits containing immune complexes
and classical complement pathway components are char-
acteristic for (primary or secondary) MPGN I or other
autoimmune diseases, C3 and C5b-9 containing deposits
within the lamina densa of the GBM are indicative for
alternative complement pathway activation and can be found
in MPGN II/DDD and in (resolving) poststreptococcal
glomerulonephritis.5,14
By contrast, Servais et al.1 recently described a group of
patients with a glomerulonephritis characterized by overt
isolated mesangial (and subendothelial) C3 deposition with-
out deposition of immunoglobulins, termed glomerulone-
phritis C3. The phenotypical presentation is variable and
ranges from an atypical hemolytic uremic syndrome- to a
MPGN II/DDD-type picture or—structurally spoken—from
a disease affecting endothelial cells to a disease affecting the
GBM. The type of underlying alternative complement
pathway dysregulation is relevant for the phenotype as risk
factors for atypical hemolytic uremic syndrome (for example,
mutations in CFH, immunohistochemical finding, or
membrane cofactor protein) direct injury toward the
endothelial cells, and risk factors for MPGN II/DDD (for
example, C3NeF) toward the GBM, respectively.
Glomerular lesions seen at the ultrastructural level in the
biopsies of the two reported patients were different from
MPGN II/DDD in so far as mesangial deposits were more
prominent than peripheral and, even more so, because no
linear hypereosinophilic deposits were seen in the peripheral
basement membrane. The predominance of C3 (and C5b-9)
deposits seen by immunohistochemistry was nonetheless
suggestive of a diagnosis in the MPGN II/DDD spectrum.
The morphology, however, was similar if not identical to the
cases recently described by Servais et al.1 as glomerulone-
phritis with isolated C3 deposits.
Interestingly, the CFH mutation of the two presented
patients was localized to the regulatory domain SCR4 of
CFH. Using in vitro assays we have previously shown that
while binding to endothelial cells and C3b was unaffected,
cofactor and decay-accelerating activity of the mutant CFH
protein was severely reduced.2 Like CFH deficiency, loss of
complement regulatory activity of CFH seems to predispose
for a glomerulopathy similar (but not identical) to MPGN II/
DDD that can be caused, for example, by the absence of CFH
because of a block of protein secretion.
As impaired control of the alternative complement
pathway caused by a functional CFH defect was identified
as underlying cause, chronic therapy with fresh frozen plasma
(FFP) to substitute intact CFH was initiated. On the basis of a
CFH half-life of 6 days,15 FFP infusions (10–15 ml/kg body
weight/infusion at an infusion rate of 5–7.5 ml/kg body
weight) were given every 14 days for a total of 36 months. A
representative time course of C3 levels over the period of one
treatment cycle indicates treatment efficacy with immediate
C3 increase upon FFP infusion in both patients (Figure 5).
Figure 4 | Typical electron microscopic picture of
MPGN II/DDD. Short linear highly osmiophilic deposits within
the basement membrane and nodular deposits in the
mesangium. Light microscopy and immunohistochemistry
(C3, C5b-9) were indistinguishable from the two presented
patients. (Primary fixation in buffered formalin (4%), postfixation
in glutaraldehyde (3%),  4400).
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Figure 5 | C3 time course before, immediately after, and þ 5,
þ 24, þ 120 min after start of infusion of 10–15 ml/kg body
weight FFP in both patients. In patient 1, complement analysis
revealed a prompt increase of C3 after FFP infusion that gradually
decreased to pretreatment levels after 120 h. In patient 2,
post-FFP C3 increase was followed by a more rapid decrease
to pretreatment levels than in patient 1.
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During chronic plasma therapy, patient 1 never showed
symptoms of disease relapse. Patient 2, however, had several
episodes of gross hematuria and proteinuria triggered by
upper airway infections. These flares were successfully treated
with additional FFP infusions. In both patients, renal
function remained normal, blood pressure did not exceed
normal range, and persistent proteinuria did not develop
over the entire observation treatment period of 36 months.
Chronic FFP treatment was well tolerated and no severe side
effects occurred. Of note, despite chronic exposure to large
amounts of plasma proteins, development of anti-CFH
autoantibodies was not observed in either patient.
In summary, we here report—to our knowledge for the
first time—successful long-term plasma therapy (36 months)
of two patients with C3 deposition glomerulopathy because
of defective alternative complement pathway control caused
by a functional CFH defect. The patients could efficiently and
safely be treated with FFP infusions in the long-term and
relapses responded favorably to additional FFP infusions.
Anti-CFH autoantibodies, although not detected in the
presented patients, may challenge treatment efficacy in the
long run and must therefore be monitored.
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